Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

BACKGROUND: KRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + P) versus docetaxel + carboplatin + trastuzumab + pertuzumab (TCH + P) in patients with HER2-positive, stage II–III breast cancer. We investigated the association of biomarkers with clinical outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: de Haas, Sanne L., Slamon, Dennis J., Martin, Miguel, Press, Michael F., Lewis, Gail D., Lambertini, Chiara, Prat, Aleix, Lopez-Valverde, Vanesa, Boulet, Thomas, Hurvitz, Sara A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832665/
https://www.ncbi.nlm.nih.gov/pubmed/36631725
http://dx.doi.org/10.1186/s13058-022-01587-z

Ejemplares similares

Ejemplares similares